Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? - Wikidata - wikimedia - TriplyDB

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

http://www.wikidata.org/entity/Q48278939

about

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

http://www.wikidata.org/entity/Q48278939

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@en

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@nl

type

label

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@en

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@nl

prefLabel

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@en

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@nl

P1433

Q48278939-24524582-2DB3-4AE8-8DDD-3DFED7AFAFC7

P1476

Q48278939-A7572A05-EA2F-40D7-A723-F6C0217DF7A2

P2093

Q48278939-306CA5E8-5CAC-4B4D-B8D2-D5DF21CFB453

Q48278939-50BE376B-9EE7-4EC0-8D41-47AB1B10750E

Q48278939-6B6BC9AB-4952-4E08-AF01-9C927D61316E

Q48278939-7E3FDFF4-DE42-4C7E-8BCE-B2DF466E4730

Q48278939-8B6D90E5-5042-4C49-B077-B2BFAE220DB0

Q48278939-8E02CD46-9A32-4833-BC6C-655BE51C44E1

Q48278939-A393AF9B-007C-4591-A38E-D487D6CAEAA1

Q48278939-AD0193FB-E583-4D18-9B58-6ACD346D5605

Q48278939-BB5426E0-BD17-41AD-81D0-C9D1C497F44A

Q48278939-BBDA97DD-1F6B-427A-8348-806854C19870

P2860

Q48278939-10C5B6FF-6231-4068-9EA6-70B4407E7B0B

Q48278939-111E1F93-DF07-4290-B714-A6E800438058

Q48278939-20CE6B02-CE83-46E3-9A4E-18594E4D3F63

Q48278939-231FAFDF-A5C9-41E3-9621-E376BC96716D

Q48278939-38FA6A89-343C-4760-BD0D-89BB30ACCAD7

Q48278939-440A1BE6-5FE3-43E6-905F-3A2F85ADF6EA

Q48278939-62491B83-06FF-4C9B-B934-3F7C3AEF0340

Q48278939-718DA0E0-3503-4712-B483-591A19B58CC8

Q48278939-72C22FED-5821-4621-A009-C67B2F1FE80F

Q48278939-7A56A4D5-1E6B-427F-96D1-E70A1217D454

P304

Q48278939-45EA6C27-5F3A-4F46-8B3C-5C4F51013647

P31

Q48278939-60C8539D-E29C-4975-B2E0-1D5A4042D11B

P356

Q48278939-94AE33C5-EDFC-437B-A811-1991303ABC89

P407

Q48278939-27BBBC17-4BDE-42B1-B100-38866D4F9D45

P433

Q48278939-00414737-E4A6-4702-BD9B-45815D3FDE70

P478

Q48278939-82F171B0-679E-4939-8262-2BA08A885028

P50

Q48278939-2E88C9C7-61FE-4453-8FC6-C561C97FDDEB

Q48278939-353F484E-290C-48A6-8C34-052A8997492F

Q48278939-F36B3654-F64B-4CF5-9C70-F32A779A96C6

P577

Q48278939-310E37C3-1037-409A-BD93-6F598FAC3B0B

P698

Q48278939-6432907B-A773-4D10-820E-B7A15992791B

P932

Q48278939-D7C4B13B-B46C-4603-B8B7-EFEE9CE9E993

P356

P1433

Cancer Medicine

P1476

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

@en

P2093

Hai-Bo Qiu

http://www.w3.org/2001/XMLSchema#string

Jing-Dun Xie

http://www.w3.org/2001/XMLSchema#string

Min Huang

http://www.w3.org/2001/XMLSchema#string

Qi-Biao Su

http://www.w3.org/2001/XMLSchema#string

Shan Zhou

http://www.w3.org/2001/XMLSchema#string

Shuang Xin

http://www.w3.org/2001/XMLSchema#string

Si Liu

http://www.w3.org/2001/XMLSchema#string

Wei Zhuang

http://www.w3.org/2001/XMLSchema#string

Xiu-Hong Yuan

http://www.w3.org/2001/XMLSchema#string

Yi Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Mechanisms of cutaneous toxicities to EGFR inhibitors.

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Clinical pharmacokinetics of imatinib.

Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

P304

317-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1286

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29316372

http://www.w3.org/2001/XMLSchema#string

P932

5806097

http://www.w3.org/2001/XMLSchema#string